Status:
UNKNOWN
Gut Microbiota and Metabonomics
Lead Sponsor:
First Hospital of China Medical University
Collaborating Sponsors:
Liaoning Cancer Hospital & Institute
The Second Hospital of Shandong University
Conditions:
Stomach Neoplasms
Gut Microbiota
Eligibility:
All Genders
18-70 years
Brief Summary
To evaluate the correlation between gut microbiota and metabolites in Borrmann type IV gastric cancer; To find the effects of microflora and metabolites on target organs; To detect the mechanism of ke...
Eligibility Criteria
Inclusion
- Patients who sign informed consent.
- Borrmann classification of gastric cancer is determined by more than 2 pathologists.
- Patients with BMI 24-28.
- Karnofsky (KPS) score \>80.
Exclusion
- Patients who take any aspirin, antibiotics, prebiotics, or probiotics within 4 weeks and steroids or immunosuppressants within 6 months prior to specimen collection.
- Patients who complicate with other malignant tumors.
- Patients who complicate with diabetes, hypertension, heart disease and infectious diseases.
- Patients who complicate with inflammatory bowel disease or irritable bowel syndrome.
- Patients with metastasis.
Key Trial Info
Start Date :
February 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05205187
Start Date
February 28 2022
End Date
December 31 2025
Last Update
January 25 2022
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
The fourth People's Hospital of Changzhou
Changzhou, Jiangsu, China, 213001
2
Chaoyang Central Hospital
Chaoyang, Liaoning, China, 122099
3
The General Hospital of Fushun Mining Bureau
Fushun, Liaoning, China, 113012
4
First Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China, 121012